Newsfeeds - Spark Newswire

2 minute read

Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs

Today, 7:46 PM

New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per patient monthly when it launched in 2021.

AMGN

1 minute read

Reported Late Wednesday, Bluebird Bio Announces Pricing Of $120M Public Offering Of 20M Shares Of Common Stock At A Price Of $6/Share

By Benzinga Newsdesk

Today, 7:46 PM

bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per share,

BLUE

2 minute read

Tesla, Amazon, bluebird, Netflix, Discover Financial: Why These 5 Stocks Are Drawing Investors’ Attention Today

By Bhavik Nair

Today, 7:46 PM

Major Wall Street indices closed over 1.2% lower on Wednesday, dragged by renewed concerns of a recession as U.S. retail sales declined by the most in 12 months, down 1.1% in December as against expectations of a fall of 0.8%.

AMZN

1 minute read

PNC Financial, bluebird bio And Other Big Stocks Moving Lower On Wednesday

By Lisa Levin

Today, 7:46 PM

U.S. stocks traded lower, with the Dow Jones dropping around 300 points on Wednesday. Here are some big stocks recording losses in today’s session.

ARQQ

1 minute read

SVB Leerink Maintains Market Perform on bluebird bio, Raises Price Target to $9

By Benzinga Newsdesk

Today, 7:46 PM

SVB Leerink analyst Mani Foroohar maintains bluebird bio (NASDAQ:BLUE) with a Market Perform and raises the price target from $8 to $9.

BLUE

1 minute read

Newly Approved Drugs In US Command Over $200,000 On An Average

By Vandana Singh

Today, 7:46 PM

The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003.

BLUE

1 minute read

‘Aetna Considers A One-time Administration Of Elivaldogene Autotemcel (Skysona) Medically Necessary For Treatment Of Cerebral Adrenoleukodystrophy (Cald) When All Of The Following Criteria Are Met’ – Aetna

By Benzinga Newsdesk

Today, 7:46 PM

https://www.aetna.com/cpb/medical/data/1000_1099/1017.html

BLUE

1 minute read

FDA Allows Bluebird Bio To Resume Sickle Cell Disease Studies In Patients Below 18, With Changed Protocol

By Vandana Singh

Today, 7:46 PM

The FDA removed its partial clinical hold on Bluebird bio Inc’s (NASDAQ:BLUE) study for patients under the age of 18 in studies…

BLUE

2 minute read

FDA Lifts Partial Clinical Hold For bluebird bio’s Sickle Cell Disease Studies For Patients Under The Age of 18

By Benzinga Newsdesk

Today, 7:46 PM

bluebird bio, Inc. (NASDAQ:BLUE) today announced that the U.S. Food and Drug Administration (FDA) lifted its partial clinical hold for patients under the age of 18 in studies evaluating lovotibeglogene autotemcel

BLUE

1 minute read

Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting

By Vandana Singh

Today, 7:46 PM

Magenta Therapeutics Inc (NASDAQ:MGTA) highlighted updated data from the ongoing MGTA-117 Phase 1/2 dose-escalation trial at the American Society of Hematology…

BLUE